Q-omics provides the consensus-scored TSSK3 profile across patient tissues and cancer cell-line models. TSSK3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TSSK3 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TSSK3 RNA expression shows 20,464 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where TSSK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSSK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSSK3 survival associations across molecular data types. TSSK3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSSK3 RNA expression–survival associations across cancer types. High TSSK3 expression shows unfavorable associations in KICH and COAD, but favorable associations in HNSC, READ, BRCA and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for TSSK3 RNA expression.
This table summarizes TSSK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TSSK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSSK3 shows lower tumor expression in BRCA and higher tumor expression in COAD, HNSC, BLCA, LIHC and CHOL. The COAD box plot shows higher TSSK3 RNA expression in tumor versus normal tissue (log2 FC = +0.131, t-test p = .008).
This table shows molecular features associated with TSSK3 in patient tissues and cancer cell lines. In patient samples, TSSK3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSSK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Myeloma.
